FDA Will Not Meet Goal Dates For Pfizer's Xeljanz, Abrocitinib Applications

  • The FDA will not meet PDUFA goal dates for Pfizer Inc's PFE marketing application for abrocitinib for severe atopic dermatitis and the supplemental application for Xeljanz/Xeljanz XR (tofacitinib) for active ankylosing spondylitis. 
  • The FDA cited its ongoing review of Pfizer's post-marketing safety study, ORAL Surveillance, evaluating tofacitinib in rheumatoid arthritis patients as a factor for the extensions.
  • As communicated in April, the FDA had previously extended the PDUFA goal dates to early Q3 2021. ​
  • Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK).
  • Xeljanz (tofacitinib) is approved in the U.S. in four indications.
  • Price Action: PFE shares are up 0.05% at $41.04 during the premarket session on the last check Thursday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!